Layoff Update

Discussion in 'Daiichi-Sankyo' started by anonymous, Nov 21, 2017 at 12:13 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    The reasons behind the upcoming layoff:

    • Pradaxa goes generic Feb 2018. Will erode the minuscule Savaysa market share.
    •Welchol will be manufactured by a generic company April 2018.
    •Movantik sales are declining
    •Hydexor never launched
    •Miragabalin never launched
    •Top heavy sales force
     

  2. anonymous

    anonymous Guest

    Welchol keeps the lights on at DSI. Now that it's going bye-bye in early 2018, that means massive cuts. Expect a 30-50% reduction in staff.
     
  3. anonymous

    anonymous Guest

    Yup, with Welchol going bye-bye in April, at least 50% of sales and HO will be gone, at least. DSI is officially dead.
     
  4. anonymous

    anonymous Guest

    Time to slice and dice. Unfortunately it will be time to move on for most. Good luck to all.
     
  5. anonymous

    anonymous Guest

    Seems to be a trend with this company - layoffs every year. anyone surprised
     
  6. anonymous

    anonymous Guest

    I'm looking forward to it. If I have a choice, I'll gladly raise my hand for the severance. There's also some idiots that need to get tossed, so that's always fun to watch. My popcorn is ready. Do it Lisicki.
     
  7. anonymous

    anonymous Guest

    I heard that Jan 11th is the day!
     
  8. anonymous

    anonymous Guest

    Hiring freeze officially in effect. You know what comes next. It's an annual occurrence because KK and RL have zero ability to accurately forecast.
     
  9. anonymous

    anonymous Guest




    YES layoffs are coming! This company makes stupid decisions and entering into this screwed up pain market is a stupid decision! Whoever said we were going to be the premier pain company doesn’t know $hit!! We are going nowhere! How can people write something that has no coverage? You seriously think the forecast numbers are realistic? THey are laughable! We look like idiots!
     
  10. anonymous

    anonymous Guest

    Disagree based on exceeding forecast for MB and all products ex Savaysa and RB launch in April should be better received than MB

    Would make sense to have SARS take over cardio products as there is opportunity for Inj there and let specialty focus on pain

    A lot of whining on here, I agree some managers are treating reps like children which is annoying, but there is opportunity to sell the portfolio out there and DSI needs positive folks to do this as none of these products sell themselves

    But, annual layoffs do seem to be a thing so who knows, just go out there and sell something. Ho ho ho
     
  11. anonymous

    anonymous Guest


    Yes!
     
  12. anonymous

    anonymous Guest

    they need us for roxy, i don't believe this, not again. we need some stability here,try to be positive and feel the peel
     
  13. anonymous

    anonymous Guest

    Do they "need us" ? I don't believe there is going to be a January restructure but there is going to be one! It is a concern that so many companies are getting out of the pain franchise and we are trying to build one? Maybe DSI will build a dominant pain franchise around MB and RB...but it seems like we are sailing into the storm when everyone else is heading for shore.
     
  14. anonymous

    anonymous Guest

    C'mon... is anyone naive enough to think the ax is not being sharpened right now for another massacre! Welchol is PURE profit and without it we are cooked! The best we can hope for is RL gets what's coming. His antics would make Weinstein and Lauer blush!
     
  15. anonymous

    anonymous Guest

    Hey fool. Savaysa is no longer being sold by us as of Jan 1st. So what "cardio" products are you talking about? I'm sure you're first on the list to get cut. Open your eyes.
     
  16. anonymous

    anonymous Guest

    What Is up with the meeting in March then ?
     
  17. anonymous

    anonymous Guest

    the meeting will be for whoever is remaining. Not unheard of for meetings to be scheduled before a layoff or realignment. Think about it. What better way to calm everyone down and make it seem like it’s business as usual so people don’t stop working or quit. Don’t worry your flights are insured. They will get most of their money back.
     
  18. anonymous

    anonymous Guest

    get a clue the meeting is for Injectafer reps only and it's at the same time as a new drug coming to market, this came out like months ago, no striker in my district was invited
     
  19. anonymous

    anonymous Guest

    No strikers were invited in your district? You mean no specialty?
     
  20. anonymous

    anonymous Guest

    Roxy is supposed to launch in April, but there's a national sales meeting for Injectafer reps only the last week of March. Put the puzzle together.